Eurofins Scientific, a provider of bioanalytical testing, has opened its new 65,800-ft² manufacturing and services facility in Louisville, KY. The facility functions as the Group’s central genomics lab in North America, focusing on the custom production of DNA and RNA oligonucleotides synthetic gene synthesis, and genomics services including DNA sequencing, synthetic biology, and next generation sequencing (NGS).

Since 2005, Eurofins has expanded or modernized more than 350,000m² of lab space, and the company plans to add another 120,000m² by the end of 2017. The Louisville facility will serve as a multi-functional hub and will also house other activities such as food and microbiology testing.

The company will introduce new synthesis technology in the new facility aimed at increasing quality and reliability in its oligonucleotides production capabilities. Quality standards implemented during construction are supported by several internationally recognized certifications such as ISO 9001:2008, ISO 13485: 2003 and an FDA certification for GMP production.

Dr. Gilles Martin, Eurofins Scientific chief executive officer, “We are proud to open our newest genomics competence center in Louisville, KY. Our ambition is to make it the most modern and innovative facility of its kind in the world. This state-of-the-art laboratory reflects the Group’s commitment to quality, innovation, and to contributing to the advancement of scientific research and health sciences around the globe.”